Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data

Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data

Objective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. Materials and Methods: A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin...

Full description

Bibliographic Details
Main Authors: Müzeyyen Aslaner Ak, Ayfer Gedük, İbrahim Halil Açar, Merve Gökçen Polat, Cenk Sunu, Ali Zahit Bolaman, Tuba Hacıbekiroğlu, Birol Güvenç, Şehmus Ertop
Format: Article
Language:English
Published: Galenos Publishing House 2023-06-01
Series:Turkish Journal of Hematology
Subjects:
myelodysplastic syndrome
low-risk
intermediate-1- risk
epoetin alfa
darbepoetin alfa
long-term
treatment response
duration of response
transfusion dependence
Online Access:https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-47715

Internet

https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-47715

Similar Items